[1]韩廷超,王忠,申梦圆.载药微球对比碘化油肝动脉化疗栓塞联合局部热消融治疗巨块型肝癌的疗效分析[J].介入放射学杂志,2024,33(09):989-994.
　HAN Tingchao,WANG Zhong,SHEN Mengyuan..Drug-eluting bead TACE versus iodized oil TACE combined with local thermal ablation for the treatment of massive hepatocellular carcinoma[J].journal interventional radiology,2024,33(09):989-994.

点击复制

载药微球对比碘化油肝动脉化疗栓塞联合局部热消融治疗巨块型肝癌的疗效分析()

PDF下载中关闭

• 
• 
• 

分享到：

参考文献/References:

［1］Ge NJ，Wang HB，He CJ，et al. Optimal interventional treatment for liver cancer：HAIC，TACE or iTACE?［J］. J Interv Med，2023，6：59-63.
［2］Cheng K，Cai N，Zhu J，et al. Tumor-associated macrophages in liver cancer：from mechanisms to therapy［J］. Cancer Commun（Lond），2022，42：1112-1140.
［3］中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗指南（2022年版）［J］.中华消化外科杂志，2022，21：143-168.
［4］Xu Y，Zhang Y，Zheng C，et al. Thermal ablation versus hepatic resection for colorectal cancer with synchronous liver metastases：a propensity score matching study［J］. Eur Radiol，2022，32：6678-6690.
［5］Deng M，Li SH，Guo RP. Recent advances in local thermal ablation therapy for hepatocellular carcinoma［J］. Am Surg，2023，89：1966-1973.
［6］Li J，Wang N，Shi C，et al. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma［J］. J Cancer Res Ther，2021，17：733-739.
［7］Eisenhauer EA，Therasse P，Bogaerts J，et al. New response evaluation criteria in solid tumours：revised RECIST guideline（version 1.1）［J］. Eur J Cancer（1965），2009，45：228-247.
［8］Luo L，He X，Li K，et al. Thermal ablation of medium-sized hepatocellular carcinomas using intraoperative ultrasound fusion imaging：a propensity score-matched analysis［J］. Clin Res Hepatol Gastroenterol，2021，45：101581.
［9］Liu YM，Ren YQ，Song SL，et al. Pyogenic liver abscess in non-liver cancer patients and liver cancer patients treated with TACE：etiological characteristics，treatment，and outcome analysis［J］. Kaohsiung J Med Sci，2023，39：87-94.
［10］Brown AM，Kassab I，Massani M，et al. TACE versus TARE for patients with hepatocellular carcinoma：overall and individual patient level meta analysis［J］. Cancer Med，2023，12：2590-2599.
［11］Odet J，Pellegrinelli J，Varbedian O，et al. Predictive factors of local recurrence after colorectal cancer liver metastases thermal ablation［J］. J Imaging，2023，9：66.
［12］Minier C，Hermida M，Allimant C，et al. Software-based assessment of tumor margins after percutaneous thermal ablation of liver tumors：a systematic review［J］. Diagn Interv Imaging，2022，103：240-250.
［13］Shirono T，Iwamoto H，Niizeki T，et al. Durable complete response is achieved by balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma［J］. Hepatol Commun，2022，6：2594-2604.
［14］Zhang W，Wu L，Chen L，et al. The efficacy of drug-eluting bead or conventional transarterial chemoembolization plus apatinib for hepatocellular carcinoma with portal vein tumor thrombus［J］. Sci Rep，2022，12：5725.
［15］Ye T，Shao SH，Ji K，et al. Evaluation of short-term effects of drug-loaded microspheres and traditional transcatheter arterial chemoembolization in the treatment of advanced liver cancer［J］. World J Gastrointest Oncol，2022，14：2367-2379.
［16］袁福建，张守林，黄少鹏，等.载药微球肝动脉化疗栓塞联合射频消融术治疗巨块型肝癌的研究［J］.浙江医学，2023，45：288-292.
［17］Zhang K，Liu Q，Liu B，et al. Primary α-fetoprotein positive hepatoid adenocarcinoma of the lung：a case report［J］. Zhonghua Jie He He Hu Xi Za Zhi，2023，46：700-707.
［18］Zhu HQ，Wang DY，Xu LS，et al. Diagnostic value of an enhanced MRI combined with serum CEA，CA19-9，CA125 and CA72-4 in the liver metastasis of colorectal cancer［J］. World J Surg Oncol，2022，20：401.
［19］Hu BY，Zou TT，Qin W，et al. Inhibition of EGFR overcomes acquired lenvatinib resistance driven by STAT3-ABCB1 signaling in hepatocellular carcinoma［J］. Cancer Res，2022，82：3845-3857.
［20］Wei H，Xu Z，Chen L，et al. Long non-coding RNA PAARH promotes hepatocellular carcinoma progression and angiogenesis via upregulating HOTTIP and activating HIF-1α/VEGF signaling［J］. Cell Death Dis，2022，13：102.
［21］Hossen MA，Reza MS，Harun-Or-Roshid M，et al. Identification of drug targets and agents associated with hepatocellular carcinoma through integrated bioinformatics analysis［J］. Curr Cancer Drug Targets，2023，23：547-563.
［22］张玉蓉，王晓栋，朱晓宁，等.原发性肝癌热消融术后并发膈疝的研究进展［J］.临床肝胆病杂志，2021，37：2939-2942.
［23］李梅，宋娟荣，翟鹏涛，等.载药微球在原发性肝癌TACE治疗中疗效及安全性分析［J］.介入放射学杂志，2021，30：186-190.
［24］李坤峰，郑睿，胡章明.CalliSpheres载药栓塞微球加载表柔比星治疗不可切除原发性肝癌的疗效［J］.介入放射学杂志，2023，32：131-135.
［25］黄洪华，徐爱兵，田思源，等.DEB-TACE治疗乏血供肝恶性肿瘤23例［J］.介入放射学杂志，2021，30：485-488.
［26］王浩，马军杰，戴献毅.载药脂微球配合肝动脉栓塞化疗治疗老年肝细胞癌的效果及对生存获益、PD-L1、PD-1水平影响［J］.世界华人消化杂志，2021，29：647-654.
［27］王玉峰，曾嘉，何东风.碘化油化疗药物乳剂联合D-TACE对比cTACE治疗肝细胞癌的临床价值［J］.介入放射学杂志，2022，31：800-804.